CDKN1B
Reaktivität: Human
WB, IHC, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Western Bloting: 1/500 - 1/2000. ELISA: Propose dilution 1/10000. Not yet tested in other applications. Determining optimal working dilutions by titration test.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Fentress: "Streams and patterns in behavior as challenges for future technologies." in: Behavior research methods, Vol. 41, Issue 3, pp. 765-71, (2009) (PubMed).
Duncan, Al-Attar, Rolland, Harper, Spendlove, Durrant: "Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer." in: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, Vol. 29, Issue 1, pp. 8-18, (2009) (PubMed).
Lee, Kim: "The function of p27 KIP1 during tumor development." in: Experimental & molecular medicine, Vol. 41, Issue 11, pp. 765-71, (2009) (PubMed).
P27 KIP 1 is a cell cycle regulatory mitotic inhibitor of cdk activity. p27 KIP 1 is a candidate tumor suppressor gene, and has been proposed to function as a possible mediator of TGF beta induced G1 arrest. p27 KIP 1 is up regulated in response to antimitogenic stimuli. The increased protein expression of p27 results in cellular arrest by binding to cyclin/Cdk complexes such as cyclin D1/Cdk4. Decreased levels of p27Kip1, mainly due to proteosomal degradation, are found in various epithelial tumors originating from lung, breast, colon, ovary, esophagus, thyroid and prostate. Tissue specificity: Expressed in all tissues tested. Highest levels in skeletal muscle, lowest in liver and kidney. Synonyms: KIP1, MEN4, CDKN4, MEN1B, P27KIP1, CDKN1B